AGL 38.02 Increased By ▲ 0.08 (0.21%)
AIRLINK 197.36 Increased By ▲ 3.45 (1.78%)
BOP 9.54 Increased By ▲ 0.22 (2.36%)
CNERGY 5.91 Increased By ▲ 0.07 (1.2%)
DCL 8.82 Increased By ▲ 0.14 (1.61%)
DFML 35.74 Decreased By ▼ -0.72 (-1.97%)
DGKC 96.86 Increased By ▲ 4.32 (4.67%)
FCCL 35.25 Increased By ▲ 1.28 (3.77%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 13.17 Increased By ▲ 0.42 (3.29%)
HUBC 127.55 Increased By ▲ 6.94 (5.75%)
HUMNL 13.50 Decreased By ▼ -0.10 (-0.74%)
KEL 5.32 Increased By ▲ 0.10 (1.92%)
KOSM 7.00 Increased By ▲ 0.48 (7.36%)
MLCF 44.70 Increased By ▲ 2.59 (6.15%)
NBP 61.42 Increased By ▲ 1.61 (2.69%)
OGDC 214.67 Increased By ▲ 3.50 (1.66%)
PAEL 38.79 Increased By ▲ 1.21 (3.22%)
PIBTL 8.25 Increased By ▲ 0.18 (2.23%)
PPL 193.08 Increased By ▲ 2.76 (1.45%)
PRL 38.66 Increased By ▲ 0.49 (1.28%)
PTC 25.80 Increased By ▲ 2.35 (10.02%)
SEARL 103.60 Increased By ▲ 5.66 (5.78%)
TELE 8.30 Increased By ▲ 0.08 (0.97%)
TOMCL 35.00 Decreased By ▼ -0.03 (-0.09%)
TPLP 13.30 Decreased By ▼ -0.25 (-1.85%)
TREET 22.16 Decreased By ▼ -0.57 (-2.51%)
TRG 55.59 Increased By ▲ 2.72 (5.14%)
UNITY 32.97 Increased By ▲ 0.01 (0.03%)
WTL 1.60 Increased By ▲ 0.08 (5.26%)
BR100 11,727 Increased By 342.7 (3.01%)
BR30 36,377 Increased By 1165.1 (3.31%)
KSE100 109,513 Increased By 3238.2 (3.05%)
KSE30 34,513 Increased By 1160.1 (3.48%)

Tears and fears as India's huge coronavirus vaccine push falters

  • "Now (inoculations) are picking up satisfactorily... Yesterday (Friday), we met 80-90 percent of our targets across vaccination stations."
Published January 24, 2021

GREATER NOIDA: India's huge coronavirus vaccination drive is behind schedule, with a third of recipients not showing up for appointments because of safety fears, technical glitches and a belief that the pandemic is ending.

After one week, India has vaccinated 1.4 million people, or 200,000 people per day. It had initially hoped to process 300,000 per day before ramping up the rollout and inoculating 300 million by July.

At the Sharda Hospital in Greater Noida near New Delhi, pharma student Khushi Dhingra, 17, hugged a friend and wept as she waited to get her shot.

"I am very afraid. I hate needles and I am worried about side effects," she told AFP.

"My papa is very worried too. He is calling me again and again to make sure I am okay."

"There are about 80 students in my batch but only two have opted to get the shot," said nursing student Sakshi Sharma, 21, in Greater Noida.

"My friends are saying there will be side effects, that you can even get paralysis."

India is using two shots for its drive.

One is Covishield, a locally produced version of the Oxford-AstraZeneca vaccine, which has been approved and safely used in a number of other countries after completing Phase 3 human trials.

The other -- Covaxin -- was developed locally by Bharat Biotech and has not yet completed Phase 3 trials, though the government has insisted it is "110 percent safe".

WhatsApp worries

Side effects are a common fear, with a few cases of severe reactions -- and even deaths -- reported widely in the media and circulating wildly on Facebook and WhatsApp.

In the eastern state of West Bengal, health chief Ajoy Chakraborty said that turnout was just under 70 percent, calling it "not encouraging".

"We could have achieved our target if some hadn't backed out after seeing television reports of adverse effects following immunisation," Chakraborty said.

But Alisha Khan, 20, a nursing student in Greater Noida, said people were also hesitant because of the "rushed" approval of Covaxin.

"Why are they trying to experiment on us? First, they should have completed trials in a proper way," Khan told AFP. "I am shivering already out of fear."

Coronavirus complacency

Dhingra, in the end, did not get a shot after staff realised she was under 18. She had, however, received a text telling her to come for the vaccination from the IT system managing the mammoth process. The government says that this and other glitches are being ironed out.

One was that if a person did not show up for vaccination, someone else could not simply take their place.

This led to unfinished vaccine vials -- which contain a certain number of doses and have to be used that day -- being thrown away.

Also hurting the effort is complacency with the number of coronavirus infections and deaths in India falling sharply in recent months.

"In the beginning when there was lockdown, (villagers) were very scared of the coronavirus," said Asha Chauhan, 30, who is part of vaccination efforts in rural areas.

"Now that fear has gone because cases have come down. They feel corona has gone from our country now," she said. "They fear they will die if they take the vaccine."

Selfie zones

Many of the 30 million people due for jabs in the first phase are health workers who have seen the deadly pandemic close up -- yet many of them are hesitant.

This needs to addressed before the vaccine is rolled out to the wider Indian population, experts say, where vaccine scepticism is already rife.

"They must launch awareness campaigns in every nook and corner of the country," said Anita Yadav, 25, an auxiliary nurse and midwife, told AFP.

The government has attempted to boost participation, even adapting a classic Bollywood song with lyrics telling people not to believe false rumours.

One Delhi hospital has set up a "selfie zone" for satisfied recipients to take photos. And vaccination centres have started playing light, soothing music in waiting rooms.

"All the top clinicians and doctors have taken the jab and we're pushing the videos of them taking the shot for circulation and it has been helping in overcoming any hesitancy," said Dr Qazi Haroon, an immunisation officer in Kashmir.

"Now (inoculations) are picking up satisfactorily... Yesterday (Friday), we met 80-90 percent of our targets across vaccination stations."

Shahid Jameel, a virologist and academic, said that a country like India was bound to have teething problems.

"Once the frontline workers are given the jabs," Jameel told AFP, "confidence will slowly build up."

Comments

Comments are closed.